

1 **Title**

2 Phenotypic spectrum of *FAM47E-SHROOM3* haplotype composition in a general population
3 sample

4

5 **Authors**

6 Dariush Ghasemi-Semeskandeh^{1,2,3}, Eva König¹, Luisa Foco¹, Nikola Dordevic¹, Martin Gögele¹,
7 Johannes Rainer¹, Markus Ralser⁴, Dianne Acoba^{5,6}, Francisco S. Domingues¹, Dorien J. M.
8 Peters², Peter P. Pramstaller¹, Cristian Pattaro¹

9

10 1. Institute for Biomedicine, Eurac Research, Bolzano, Italy.

11 2. Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.

12 3. Health Data Science Centre, Human Technopole, V.le Rita Levi-Montalcini, 1, Milan 20157,
13 Italy.

14 4. Institute of Biochemistry, Charité - Universitätsmedizin Berlin, Berlin, Germany.

15 5. Clinical Renal, Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM),
16 BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

17 6. Institut Necker Enfants-Malades (INEM), Institut National de la Santé et de la Recherche
18 Médicale (INSERM) U1151, Université Paris Cité, Paris, France

19

20 **Corresponding authors**

21 Dariush Ghasemi-Semeskandeh
22 Human Technopole, Health Data Science Centre
23 V.le Rita Levi-Montalcini, 1, Milan 20157, Italy.

24 Email: ghasemi.dariush@yahoo.com

25

26 Cristian Pattaro
27 Eurac Research, Institute for Biomedicine
28 Via Volta 21, I-39100 Bozen/Bolzano
29 T +39 0471 055 527

30 Email: cristian.pattaro@eurac.edu

31 **Abstract**

32 Genome-wide association studies identified a locus on chromosome 4q21.1, spanning the
33 *FAM47E*, *STBD1*, *CCDC158*, and *SHROOM3* genes, as associated with kidney function markers.
34 Functional studies implicated *SHROOM3*, encoding an actin-binding protein involved in cell
35 shaping, into podocyte barrier damage. Despite the locus was also found associated with
36 electrolytes, hematological and cardiovascular traits, systematic explorations of functional
37 variants across all the genes in the locus are lacking.

38 We reconstructed haplotypes covering the whole locus on 12,834 participants to the
39 Cooperative Health Research in South Tyrol (CHRIS) study, using genotypes imputed on a whole-
40 exome sequencing reference panel of a subsample of 3,422 participants. Haplotypes included
41 146 exonic and intronic variants over the four genes and were tested for association with 73
42 serum, urine and anthropometric traits, 172 serum metabolite and 148 plasma protein
43 concentrations using linear regression models.

44 We identified 11 haplotypes with 2% to 24% frequency. Compared to the most common
45 haplotype, most haplotypes were associated with higher levels of the creatinine-based estimated
46 glomerular filtration rate and lower serum magnesium levels. The second most common
47 haplotype (12% frequency) was additionally associated with lower dodecanoyl-, hydroxyvaleryl-
48 and tiglyl-carnitine serum concentrations. A haplotype of 4% frequency was also associated with
49 lower red blood cell count, hemoglobin, and hematocrit levels. A haplotype of 2% frequency was
50 associated with serum glutamine and putrescine concentrations. Cluster analysis revealed
51 distinct groups of traits and of haplotypes.

52 The *FAM47E-SHROOM3* locus exhibits haplotype variability that corresponds to marked
53 pleiotropic effects, implicating the existence of population subgroups with distinct biomarker
54 profiles.

55

56 **Keywords**

57 SHROOM3; FAM47E; haplotype; kidney; population; Cooperative Health Research In South
58 Tyrol (CHRIS) study

59 Introduction

60 A genetic locus on chromosome 4q21.1 has been prominently associated with multiple markers
61 of kidney function, including the estimated glomerular filtration rate based on serum creatinine
62 (eGFR_{crea}) or cystatin C¹⁻⁶ and albuminuria.⁷ The genetic associations lie within two
63 recombination hotspots that embed a high linkage disequilibrium (LD) region spanning four genes:
64 Family With Sequence Similarity 47 Member E (*FAM47E*); Starch Binding Domain 1 (*STBD1*);
65 Coiled-Coil Domain Containing 158 (*CCDC158*); and the first exons of the Shroom Family
66 Member 3 (*SHROOM3*).

67 Follow-up functional studies have mainly focused on *SHROOM3*, which encodes a PDZ-
68 domain-containing protein regulating cell shape, neural tube formation⁸ and epithelial
69 morphogenesis. *SHROOM3* is involved in maintaining normal podocyte structure,⁹ particularly
70 through binding of the TCF7L2 transcription factor.¹⁰ *Shroom3* modulates the actomyosin network
71 which maintains podocyte architecture.¹¹ Variants altering the *SHROOM3* actin-binding domain
72 may cause podocyte effacement and glomerular filtration barrier impairment.⁹ Furthermore,
73 *Shroom3* knockdown causes albuminuria and podocyte foot process effacement in mice as well
74 as defective lamellipodia formation in podocytes and disrupted slit diaphragms in rat glomerular
75 epithelial cells.¹² *SHROOM3* alterations may also implicate craniofacial alterations^{13,14} and cardiac
76 defects.¹⁵ Less attention has been dedicated to the other genes in the locus.

77 Beyond kidney function, genetic variants at this locus are associated with diverse
78 phenotypes, including platelets,¹⁶ hemoglobin (HGB),¹⁶ serum magnesium,¹⁷ and Parkinson's
79 disease.¹⁸ The alleles associated with lower eGFR_{crea} are also associated with lower urine
80 albumin-to-creatinine ratio (UACR),⁷ despite glomerular *Shroom3* knockdown should induce
81 albuminuria.¹⁹

82 Altogether, this evidence suggests that, while *SHROOM3* is a promising molecular target
83 for chronic kidney disease (CKD) prevention,¹⁰ the genetic variability of the whole *FAM47E*-
84 *SHROOM3* locus warrants more extensive investigations to comprehensively characterize the
85 corresponding phenotypic spectrum. This may also clarify whether the previously reported,
86 apparent mediatory role of serum magnesium on the association between eGFR_{crea} and the
87 locus²⁰ reflects real biological mechanisms or rather the joint genetic regulation of the two traits.

88 To investigate the presence of distinct genetic profiles involving diverse phenotypic
89 manifestations, we conducted a haplotype analysis of genetic variants in the *FAM47E-SHROOM3*
90 region imputed from a whole-exome sequencing (WES) panel, in an Alpine population-based

91 study. Notoriously, haplotype analysis does not illuminate causal mechanisms but instead, it is a
92 population genetic tool to explore a locus's heterogeneity in population. Reconstructed haplotypes
93 were tested for association against 73 clinical traits, 172 target serum metabolites, and 148
94 plasma protein markers.

95

96 **Methods**

97 *Study sample*

98 We analyzed data from the Cooperative Health Research in South Tyrol (CHRIS) study,
99 conducted in South Tyrol, Italy, between 2011 and 2018.²¹ Following overnight fasting, 13,393
100 participants underwent early morning blood drawing, urine collection, anthropometric
101 measurements, and blood pressure measurements.²² Health and lifestyle information was
102 gathered through computer-based standardized questionnaire-based interviews. The analysis
103 overview is given through a flowchart in **Figure 1A**.

104

105 *Genomics*

106 All DNA samples were genotyped on the Illumina HumanOmniExpressExome or Omni2.5Exome
107 arrays and called with GenomeStudio v2010.3 with default settings on GRCh37, lifted to GRCh38
108 via CrossMap v0.6.5. Variants with GenTrain score <0.6, cluster separation score <0.4, or call
109 rate <80% were considered technical failures and discarded. Variants present on both arrays
110 were submitted to further quality control (QC) and removed if monomorphic or not in Hardy-
111 Weinberg equilibrium ($P < 10^{-6}$). Samples with <0.98 call rate were removed.

112 Samples from a subset of 3840 participants underwent WES (xGen® Exome Research
113 Panel v1.0; McDonnell Genome Institute, Washington University). Data processing, read
114 alignment and QC were conducted as detailed previously.^{23,24} We retained 3422 samples with a
115 post-QC mean target coverage of 68.4X.

116 WES data were used as a population-specific reference panel for genotype imputation
117 onto the whole CHRIS sample as reported previously.²³ Based on 181 WES samples excluded
118 from the reference panel for testing purposes, we observed excellent imputation quality between
119 imputed genotypes and sequenced hard-calls (median Pearson's correlation=0.99).²³

120

121 *Clinical, metabolomics, and proteomics traits*

122 Information on genotype data and clinical traits was available for 12,834 participants. Clinical traits
123 included blood and urinary markers, diastolic and systolic blood pressure (SBP), and body mass
124 index (BMI; **Suppl. Tab. 1**). eGFR_{crea} was estimated with the race-free CKD-EPI equation using
125 the R package 'nephro' v1.3.0.²⁵ Laboratory assay effects²⁶ were addressed through quantile
126 normalization as detailed previously.²⁰ Missing values were imputed to the median.

127 Targeted metabolomics analysis involved a subset of 7252 participants, whose serum
128 samples were analyzed with the AbsoluteIDQ p180 kit (Biocrates Life Sciences AG, Innsbruck,
129 Austria). Normalization and QC of the 188 measured metabolites are described elsewhere.²⁷ To
130 increase sample homogeneity, pregnant women and individuals of non-European descent were
131 excluded. Metabolites with >20% missing data were excluded. Missing values were imputed to
132 the median, otherwise. QC left 172 high-quality metabolites available on 6642 samples (**Suppl.**
133 **Tab. 1**).

134 On a subset of 4087 participants we measured 148 plasma proteins, using mass-
135 spectrometry-based scanning SWATH.²⁸ Data generation and processing was described
136 elsewhere.²⁹ After merging with the genetic data, 3535 participants remained for the analysis
137 (**Suppl. Tab. 1**).

138

139 *Haplotype association analysis*

140 The region of interest on chromosome 4 was bounded by two recombination peaks at positions
141 76,251,700 and 76,516,500, encompassing 152 WES-based imputed variants spanning
142 *FAM47E*, *FAM47E-STBD1*, *CCDC158* and *SHROOM3* (**Figure 1B**). Retaining 146 variants with
143 minor allele frequency>0.0001 and with imputation quality index $R_{sq}>0.3$ (median $R_{sq}=0.87$;
144 **Suppl. Tab. 2**), haplotype reconstruction and regression analysis was conducted using the
145 *haplo.glm* function of the R package 'haplo.stats' v1.8.9, exploiting an expectation-maximization
146 algorithm for haplotype inference³⁰ (**Supplementary Methods**). Alleles were aligned on the major
147 allele as the reference. Haplotypes with <0.02 frequency were collapsed into a rare-haplotype
148 category. We fitted linear association models on the inverse normal transformation of each trait,
149 metabolite, and protein, including haplotypes as predictors and adjusting for age, sex, and the
150 first 10 genetic principal components (PCs), estimated on the genotyped autosomal variants, to
151 control for population structure.

152 Among the 73 considered clinical traits, 18 traits have been previously reported with
153 genome-wide significant associations with variants in the locus (GWAS Catalog interrogation at
154 <https://www.ebi.ac.uk/gwas/> on 23-Aug-2023; **Figure 2A**). These traits were tested for
155 association with the haplotypes at the significance level $\alpha=0.05$, considering the strong prior
156 evidence of association. For the remaining clinical traits, the 172 metabolites, and the 148
157 proteins, we set α at $0.05/50=0.001$, $0.05/88=5.68\times 10^{-4}$ and $0.05/113=4.42\times 10^{-4}$, respectively,
158 where 50, 88, and 113 were the number of independent PCs necessary to explain 95% of each
159 dataset's variability (analyses conducted with the *prcomp* function in the R package 'stats' v4.3.0).

160

161 *Cluster analysis*

162 We performed hierarchical clustering of the z-scores obtained from the significant associations
163 between haplotypes and traits and metabolites. Similarity was based on the Euclidean distance
164 and clustering implemented based on the 'Ward D2' approach via *hclust* in the 'stats' R package.
165 We applied the Silhouette method to the non-scaled z-scores to determine the optimal number of
166 clusters for haplotypes and traits, using the *fviz_nbclust* and *hcut* functions in the R package
167 'factoextra' v1.0.7, allowing a maximum of 8 and 18 clusters, respectively.

168

169 *Variant annotation*

170 Genetic variants were annotated with the Ensembl Variant Effect Predictor v100.2
171 (<http://www.ensembl.org/info/docs/tools/vep/index.html>), predicting the most severe
172 consequences with the 'split-vep' plugin. LD between WES-imputed variants selected for
173 haplotype analysis and previously reported common variants associated with the traits of interest
174 was assessed through the D' statistic, which reflects the underlying haplotype diversity,³¹
175 estimated using PLINK v1.9.³²

176 We queried the haplotype-tagging variants in the European ancestry datasets of the GTEx
177 Consortium v8 database (<https://gtexportal.org/home/>; 10-Aug-2023) across 48 tissues (n=65 to
178 573 samples per tissue) and in NephQTL2³³ (6-Feb-2024), to test association with the expression
179 of the four genes in the locus ($P<5\times 10^{-8}$), and across 4502 whole blood protein GWAS summary
180 results available in ³⁴ to identify protein quantitative trait loci (pQTLs) at $P<5\times 10^{-8}$ (n=35,559;
181 <https://decode.com/summarydata>; 11-Oct-2023).

182

183 Results

184 *Characterization of the FAM47E-SHROOM3 genomic variants*

185 The 12,834 participants (54.3% females) had a median age of 46 years and median eGFR_{crea}
186 level of 92.9 ml/min/1.73m²; 3.6% had eGFR_{crea}<60 ml/min/1.73m² and 5.9% had UACR>30
187 mg/g (**Table 1**). The sample appeared as an extract of the general population, with no particularly
188 prevalent clinical aspects (**Suppl. Tab. 1**).

189 Within the locus we identified 146 WES-imputed variants. They were largely intronic, but
190 also included missense variants as well as synonymous, stop-gain, splicing, and other types of
191 functional variants (**Figure 2B, Suppl. Tab. 2**). The variants were all in strong-to-perfect LD with
192 common variants previously associated with common traits (**Figure 2C**). GWAS catalog
193 interrogation showed the marked locus' pleiotropic nature (**Figure 2A; Suppl. Fig. 1**).

194 Haplotype reconstruction identified 11 haplotypes (H1 to H11) with ≥2% frequency (**Suppl.**
195 **Fig. 2**), which were uniquely tagged by 27 of the 146 variants (**Figure 2D**): rs3733251, rs3733250,
196 and rs1036788 are missense variants in *FAM47E* and rs80162610 is a splice variant at
197 *CCDC158*. Similar haplotype distributions were observed in the metabolomics and proteomics
198 subsamples (**Figure 2D**).

199 The 27 haplotype-tagging variants were not associated with *SHROOM3* expression
200 (**Figure 3A; Suppl. Tab. 3**). rs2289514, rs1876538, rs3733253, rs964051, and the missense
201 variant rs3733250 at *FAM47E* were associated with *FAM47E* expression across most tissues.
202 The remaining variants were associated with the expression of at least one among *FAM47E*,
203 *CCDC158*, and *STBD1* in different tissues. No variant was a kidney-specific eQTL for the four
204 investigated genes in the GTEx. NephQTL2 database interrogation did not identify any genome-
205 wide significant eQTLs in the glomerular and tubulointerstitial tissues (**Suppl. Tab. 4**).

206 The proteins encoded by the four genes in the locus were not included in the CHRIS or in
207 the deCODE plasma proteomic datasets [36]. However, in the latter, we observed associations
208 with proteins (**Figure 3B**) whose encoding genes are also located on chromosome 4q21.1,
209 immediately to the left of the recombination peak next to *FAM47E*: the ADP-ribosyltransferase 3
210 (NAR3) encoded by *ART3*, the N-acyl ethanolamine acid amidase (NAAA) encoded by the
211 homonymous gene, and the C-X-C motif chemokine ligand 11 (CXCL11; see **Figure 1B** for
212 localization). Twenty-two of the 27 haplotype-tagging variants were associated with at least one
213 of those three proteins. Specifically, *FAM47E* missense variant rs3733251 was associated with
214 all three proteins and with the C-X-C motif chemokine ligand 6 (CXCL6), whose encoding gene

215 seats on the contiguous 4q13 cytoband. Other variants associated with all three adjacent proteins
216 were rs6532316 in *FAM47E* and rs72657825 and rs6857452 in *CCDC158*. NAAA was associated
217 with most variants, including the *SHROOM3* intronic variant rs10006043. Variant rs6812193 in
218 *FAM47E* was additionally associated with sphingomyelin phosphodiesterase 1 (SMPD1),
219 hyaluronidase 1 (HYAL1), and the activating transcription factor 6 beta (ATF6B), whose encoding
220 genes are in different chromosomes.

221

222 *Haplotype association analyses and hierarchical clustering*

223 Haplotypes were first tested for association with the 18 traits for which there was a
224 previously reported association with single variants at the locus (**Table 2, Suppl. Tab. 5**).
225 Compared to the reference haplotype, haplotype H1 was associated with higher SBP and lower
226 levels of mean corpuscular hemoglobin (MCH), HGB and magnesium. H4 was associated with
227 lower serum magnesium and creatinine levels as well as higher eGFR_{crea}, UACR, and BMI
228 levels. H5 was associated with lower alkaline phosphatase (ALP). H6, the second most common
229 haplotype (frequency=11.6%), was associated with lower serum creatinine ($P=4.92\times 10^{-6}$) and
230 platelet count (PLT) and higher eGFR_{crea} ($P=0.004$). H7 was associated with lower serum
231 magnesium and creatinine ($P=0.044$). H8 was associated with lower serum creatinine ($P=0.001$)
232 as well as higher eGFR_{crea} ($P=2.72\times 10^{-4}$), UACR ($P=0.003$) and SBP ($P=0.019$). H9 was
233 associated with lower HGB, red blood cell count (RBC), hematocrit, magnesium, serum creatinine
234 and higher eGFR_{crea}. H10 was associated with lower magnesium levels. For the 55 remaining
235 traits without prior evidence of association with variants in the locus, we identified an additional
236 association between H4 and lower basophil levels ($P=4.18\times 10^{-4}$), after multiple testing control.

237 Haplotypes were also associated with serum metabolites (**Table 2; Suppl. Tab. 6**): H1
238 with higher phosphatidylcholine C42:0 ($P=4.39\times 10^{-4}$); H3 with lower histidine ($P=4.28\times 10^{-4}$); H10
239 with lower glutamine ($P=1.08\times 10^{-4}$) and putrescine ($P=2.26\times 10^{-4}$). H6 was associated with lower
240 dodecenoylcarnitine ($P=2.82\times 10^{-4}$), hydroxyvalerylcarnitine ($P=1.31\times 10^{-4}$), and tiglylcarnitine
241 ($P=4.48\times 10^{-4}$) concentrations. **Suppl. Fig. 3** outlines all associations between haplotypes, clinical
242 traits, and metabolites. After multiple testing control, no significant association between
243 haplotypes and the 148 targeted plasma proteins was identified (**Suppl. Tab. 7**).

244 For haplotypes associated with both clinical traits and metabolites, we repeated the
245 haplotype-metabolite association tests adjusting for the clinical traits (**Table 3**): haplotype effects
246 on metabolites remained generally unchanged, indicating independent effects, except for H6

247 effect on carnitines that was attenuated by serum creatinine adjustment, potentially indicating
248 common regulatory mechanisms.

249

250 *Cluster analyses of significant trait-haplotype associations*

251 Hierarchical clustering of the haplotype effects on the significantly associated 13 clinical
252 traits and 7 metabolites, identified 6 clusters of traits, according to the Silhouette method (**Figure**
253 **4; Suppl. Fig. 4**). Cluster 1 included red blood cells (HGB, hematocrit, RBC, MCH) and immune
254 traits (basophils). Cluster 2 grouped together putrescine, glutamine, and histidine. Cluster 3
255 included serum creatinine and magnesium. Cluster 4 involved a combination of clinical traits (PLT,
256 BMI) and metabolites (dodecenoylcarnitine). Cluster 5 included carnitines hydroxyvalerylcarnitine
257 and tiglylcarnitine. Cluster 6 included traits associated with kidney function (eGFR_{crea}, UACR),
258 blood pressure (SBP), liver transaminases (ALP) and phosphatidylcholine C42:0. When
259 clustering by haplotype, the Silhouette method identified two clusters, one grouping H1, H3, H6,
260 H9 and H10 and a second one including H2, H4, H7, and H8. Altogether, the identified cluster
261 structure suggests the existence of distinct genetic and correspondingly phenotypic
262 characteristics at *FAM47E-SHROOM3*, where individuals with specific haplotypes present
263 specific phenotypic and metabolic signatures.

264

265 **Discussion**

266 Our comprehensive investigation of 11 haplotypes derived from 146 WES-imputed variants and
267 evaluated across 393 clinical traits, metabolites, and proteins, highlights haplotypic profiles at
268 *FAM47E-SHROOM3* associated with distinct phenotype manifestations. We extend previous
269 studies on the role of *SHROOM3* on kidney function regulation,¹⁰ by additionally showing that
270 haplotypes spanning *SHROOM3* include missense variants at *FAM47E*, which seems the most
271 relevant gene in the haplotype after *SHROOM3*, raising the possibility of complex interactions.
272 Given its function of promoting histone methylation, *FAM47E* might epigenetically regulate
273 *SHROOM3* transcription. *STBD1* is involved in glycogen metabolism and protein is absent in the
274 kidney, while *CCDC158* is strictly testis specific.

275 The diffuse association of most haplotypes with both lower serum magnesium and higher
276 eGFR_{crea} suggests that the previously observed mediation between the two traits²⁰ more likely
277 reflects their joint regulation by genes in the locus. Association of haplotypes H4 and H8 with
278 lower serum creatinine and higher UACR and eGFR_{crea} at the same time, is compatible with

279 reduced muscle mass causing lower circulating creatinine and thus higher eGFR_{crea} and lower
280 urinary creatinine excretion increasing UACR. Nevertheless, H8 association with higher SBP is
281 consistent with the increased risk of incident hypertension in albuminuric individuals.³⁵ Similar
282 results were observed for H4, despite non-significant association with higher SBP. Given H4 and
283 H8 do not share any alleles at the 27 tagging variants, their similar characteristics might reflect
284 LD with functional variants outside the reconstructed haplotypes.

285 Haplotype H6 was associated with lower serum creatinine and lower acylcarnitines
286 dodecenoylcarnitine, hydroxyvalerylcarnitine, and tiglylcarnitine concentrations. Acylcarnitines
287 transport fatty acids from the cytosol into the mitochondria to produce energy through beta-
288 oxidation.³⁶ They are freely filtered by the kidney and excreted in the urine.³⁷ As kidney function
289 decreases, serum acylcarnitines should increase.³⁸ This was observed in CKD patients exhibiting
290 high serum dodecenoylcarnitine, hydroxyvalerylcarnitine and tiglylcarnitine concentrations linked
291 to low eGFR.³⁷ This aligns with our findings, suggesting that H6 might confer nephroprotection
292 through carnitine reduction. Alternatively, H6 might be in LD with *SHROOM3* alleles conferring
293 sustained structural integrity of the podocytes, resulting in better filtration capacity lowering both
294 creatinine levels and free acylcarnitines concentrations.

295 Haplotypes H9 and H1 were associated with lower levels of red blood cell traits. The
296 kidney produces erythropoietin, which is key to red blood cell production.³⁹ Lower kidney function
297 could lead to less or defective red blood cells but connection with H9 is difficult as the haplotype
298 is associated at the same time with higher eGFR_{crea}.

299 H3 carriers had lower histidine concentrations and statistically non-significant lower
300 putrescine and glutamine concentrations. Similarly, H10 carriers showed significantly lower
301 putrescine and glutamine and non-significant lower histidine. Histidine is an anti-inflammatory and
302 antioxidant factor. In CKD patients, low histidine concentrations are associated with energy
303 wasting, inflammation, oxidative stress, and mortality,⁴⁰ and histidine supplementation is
304 beneficial.⁴¹ Kidney filtration plays a role in putrescine concentrations:⁴² dialyzed patients have
305 lower serum putrescine than non-dialyzed patients.⁴³ A study on diabetic mice has postulated that
306 putrescine from ornithine catabolism activates mTOR signaling,⁴⁴ leading to podocyte loss by
307 regulating autophagy, oxidative stress, and endoplasmic reticulum stress.⁴⁵ Under glycolytic
308 blockage, podocytes use amino acids as oxidative phosphorylation substrates to produce
309 energy.⁴⁴ Less putrescine in H10 carriers might reflect well-functioning podocytes and glomeruli
310 following proper *SHROOM3* function. However, such protective effect contradicts the
311 simultaneous negative association between H3 and histidine and between H10 and glutamine.

312 Glutamine, the most abundant amino acid in humans, synthesized by most tissues and involved
313 in numerous metabolic pathways,⁴⁶ is a fundamental precursor of glutathione. Under fasting or
314 starvation, glutamine serves gluconeogenesis, helping the liver to maintain blood glucose levels
315 following glycogen-store shortages.⁴⁷ In rats, glutamine supplementation protects against STZ-
316 induced renal injury and prevents downregulation of the kidney injury molecule-1 (KIM-1),
317 neutrophil gelatinase-associated lipocalin (NGAL), TGF- β 1, and collagen-1 mRNA expressions.⁴⁸
318 In diabetic patients, glutamine supplementation decreases glycemia through increased glucagon-
319 like peptide 1 (GLP-1) secretion.⁴⁹ By presenting lower glutamine concentrations, H10 carriers
320 might have more difficulty in rebalancing glucose metabolism in the event of glucose deficiency.
321 The absence of associations of H3 and H10 with clinical traits limits further interpretation.

322 We modeled haplotypes within two recombination hotspots at positions 76,251,700 and
323 76,516,500 on chromosome 4q21.1 that clearly delineate the genetic locus associated with eGFR
324 in all GWAS reported so far. Prokop et al.¹⁰ showed that variants within those two peaks are in LD
325 with variants outside the peaks such as *SHROOM3* P1244L, located downstream the second
326 peak and associated with high CKD risk in Eastern Asia.¹⁰ They also observed that the locus is
327 associated with *TCF7L2*, a chromosome 10 transcriptional factor with a broad phenotypic
328 spectrum.⁵⁰ Our annotation analyses extend these observations, showing that several haplotype-
329 tagging variants are also associated with proteins (NAR3, CXCL11, and NAAA) whose encoding
330 genes are located immediately upstream the recombination hotspot adjacent to *FAM47E*,
331 between chromosome 4 positions 75,910,655 and 76,114,048. These associations might reflect
332 underlying longer haplotypes spanning those genes as well. NAR3 is encoded by *ART3*, which is
333 specifically expressed in the mesangium of the glomerulus.⁵¹ It warrants further investigation
334 whether joint involvement of *SHROOM3* on podocytes and *ART3* on the mesangium is possible
335 and if that might implicate relevant kidney phenotypes. *CXCL11* is a proinflammatory chemokine
336 implicated in kidney disease induced by interferon signaling.⁵² Urine CXCL11 correlates with
337 diabetic kidney disease progression⁵³ and is upregulated in the glomeruli of nephrotic syndrome
338 patients carrying *APOL1* high risk variants.⁵⁴ In mice with acute glomerular inflammation, genetic
339 deletion of *CXCL11* receptor *Cxcr3* attenuates glomerulosclerosis and albuminuria.⁵⁵ NAAA is a
340 proinflammatory protein emerging as a promising target in mouse models of parkinsonism,⁵⁶
341 without evident links to kidney function. Other associated proteins, encoded by genes in other
342 chromosomes (*SMPD1*, *HYAL1*, *ATF6B*, and *CXCL6*), may reflect either *FAM47E* transcriptional
343 activity or biological consequences of the proteins encoded by the genes tagged by the
344 haplotypes.

345 The main strength of our analysis was the availability of WES data from a subsample
346 which we used to impute exonic variants in the whole study sample of >12,000 individuals,
347 enabling the reconstruction of haplotypes with frequencies as low as 2% in the population across
348 clinical traits, metabolites, and proteins. Limitations are also present. The proteomics panel
349 included mostly highly abundant plasma proteins, none of which resulted associated with
350 haplotypes at this locus. The successful single-variant query of external proteomic datasets
351 suggests that haplotype associations with those same proteins might be identified should
352 individual-level data become available. Despite the large sample size, haplotypes are
353 multicategory variables that easily generate data sparseness, eroding statistical power. Finally,
354 consistent with GWAS studies that identified significant associations with complex traits at this
355 locus, we focused our investigation on the region bounded by the two recombination hotspots at
356 chromosome 4 positions 76,251,700 and 76,516,500: given most *SHROOM3* exons fall outside
357 this segment, this constraint has probably limited the possibility to contextualize *SHROOM3* with
358 the other genes. On the other hand, extrapolating haplotypes at arbitrary distance outside the
359 borders would have increased data sparseness.

360 In conclusion, our investigation revealed the presence of distinct genetic profiles at
361 *FAM47E-SHROOM3* associated with heterogeneous phenotypic and metabolic combinations that
362 warrant dedicated investigation.

363

364 **Ethics approval and consent to participate**

365 The Ethics Committee of the Healthcare System of the Autonomous Province of Bolzano-South
366 Tyrol approved the CHRIS baseline protocol on 19 April 2011 (21-2011). The study conforms to
367 the Declaration of Helsinki, and with national and institutional legal and ethical requirements. All
368 participants included in the analysis gave written informed consent.

369

370 **Acknowledgements**

371 The CHRIS study is conducted in collaboration between the Eurac Research Institute for
372 Biomedicine and the Healthcare System of the Autonomous Province of Bolzano-South Tyrol.
373 Investigators thank all study participants, the general practitioners of the Val Venosta/ Vinschgau
374 district, and the staff of the Silandro/Schlanders hospital and of the Autonomous Province of
375 Bolzano-South Tyrol Healthcare System for their support and collaboration. They also thank the
376 study team in Silandro/Schlanders, the CHRIS Biobank personnel, and all Institute for

377 Biomedicine colleagues who contributed to the study. Extensive acknowledgement is reported at:
378 <https://www.eurac.edu/en/institutes-centers/institute-for-biomedicine/pages/acknowledgements>.
379 CHRIS Bioresource Research Impact Factor (BRIF) code: BRIF6107. The authors thank the
380 Department of Innovation, Research and University of the Autonomous Province of Bolzano-
381 South Tyrol for covering the Open Access publication costs.

382

383 **Funding**

384 The CHRIS study was funded by the Department of Innovation, Research and University of the
385 Autonomous Province of Bolzano-South Tyrol and supported by the European Regional
386 Development Fund (FESR1157). This work was carried out within the TrainCKDis project, funded
387 by the European Union's Horizon 2020 research and innovation programme under the Marie
388 Skłodowska-Curie grant agreement H2020-MSCA-ITN-2019 ID:860977 (TrainCKDis).

389

390 **Author contributions**

391 Conceptualization of the research project: C.P., D.G.

392 Recruitment and study management: M.G., P.P.P., C.P.

393 Bioinformatics: D.G., E.K., N.D.

394 Data quality control and harmonization: M.G., J.R., M.R., L.F.

395 Statistical Analysis: D.G.

396 Results interpretation: D.G., C.P., M.G., L.F., D.A.

397 Manuscript drafting: D.G., C.P.

398 Manuscript critical revision: All authors

399

400 **Competing interests**

401 CP is consultant for Quotient Therapeutics. DA is employed by AstraZeneca. The other authors
402 declare no competing financial interests.

403

404 **Data availability**

405 The data used in the current study can be requested with an application to
406 access.request.biomedicine@eurac.edu at the Eurac Research Institute for Biomedicine.

Table 1. Main characteristics of the study sample. Data are described as median (interquartile range) or number of cases (percentage), as appropriate. Additional characteristics are described in Supplementary Table 1.

Participants' characteristics	Group of traits and sample size		
	Clinical traits (n=12,834)	Metabolites (n=6,642)	Proteins (n=3,535)
Age, years	46 (31 – 57)	46 (32 – 58)	46 (32 – 58)
Females	6,969 (54.3%)	3,650 (55.0%)	1,977 (55.9%)
eGFR _{crea} , ml/min/1.73 m ²	92.9 (81.7 – 104.1)	92.2 (81.1 – 103.5)	92.2 (80.8 – 103.3)
eGFR _{crea} < 60 ml/min/1.73 m ²	460 (3.6%)	269 (4.1%)	143 (4.1%)
UACR > 30 mg/g	752 (5.9%)	393 (5.9%)	225 (6.4%)
HbA1c > 6.5%	189 (1.5%)	97 (1.5%)	54 (1.5%)
Hypertension*	2,023 (15.8%)	1,002 (15.1%)	536 (15.2%)

* systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg

Table 2. Statistically significant* haplotype associations with blood, urine, anthropometric, and metabolic traits in the CHRIS study. No significant association was observed with proteins.

Group	Haplotype	Trait	Effect (SE)**	P-value
Clinical traits	H1	SBP	0.054 (0.023)	0.017156
		MCH	-0.063 (0.027)	0.018654
		HGB	-0.044 (0.021)	0.037743
		Magnesium	-0.056 (0.027)	0.041443
	H4	Basophils	-0.145 (0.041)	4.18E-04
		Magnesium	-0.139 (0.041)	6.74E-04
		eGFRcrea	0.089 (0.029)	0.002221
		BMI	0.118 (0.039)	0.002364
		Serum creatinine	-0.094 (0.032)	0.003637
		UACR	0.085 (0.039)	0.027938
	H5	ALP	-0.101 (0.049)	0.039383
	H6	Serum creatinine	-0.084 (0.018)	4.92E-06
		eGFRcrea	0.048 (0.017)	0.003950
		PLT	-0.052 (0.023)	0.021181
	H7	Magnesium	-0.106 (0.043)	0.014985
		Serum creatinine	-0.069 (0.034)	0.043883
	H8	eGFRcrea	0.113 (0.031)	2.72E-04
		Serum creatinine	-0.111 (0.034)	0.001136
		UACR	0.122 (0.041)	0.003278
		SBP	0.084 (0.036)	0.019310
H9	HGB	-0.069 (0.027)	0.010716	
	RBC	-0.069 (0.030)	0.022546	
	HCT	-0.063 (0.028)	0.025566	
	eGFRcrea	0.056 (0.025)	0.026760	
	Magnesium	-0.075 (0.035)	0.032351	
	Serum creatinine	-0.054 (0.028)	0.049913	
H10	Magnesium	-0.125 (0.040)	0.001810	
Metabolites	H1	Phosphatidylcholine diacyl C42:0	0.134 (0.038)	4.39E-04
	H3	Histidine	-0.215 (0.061)	4.28E-04
	H6	Dodecenoylcarnitine	-0.116 (0.032)	2.82E-04
		Hydroxyvalerylcarnitine ***	-0.122 (0.032)	1.31E-04
		Tiglylcarnitine	-0.113 (0.032)	4.48E-04
	H10	Glutamine	-0.196 (0.051)	1.08E-04
		Putrescine	-0.195 (0.053)	2.26E-04

*Statistical significance was set at $\alpha = 0.05$ for traits with prior evidence of association and $\alpha = 0.05$ to the number of principal components explaining 95% of the set variability for traits and metabolites with no prior evidence of association (see Methods). **Effects are expressed in terms of standard deviations as all traits were normalized using the inverse-normal transformation (see Methods) ***Also known as Methylmalonylcarnitine

Table 3. Covariate-adjusted haplotype-metabolite association models. Association models between each haplotype and the associated metabolite (**Table 2**) were adjusted for the traits associated with the same haplotype to assess potential mediation.

Haplotype	Phenotype	Covariate	Effect (SE)	P-value
H1	Phosphatidylcholine diacyl C42:0	SBP	0.135 (0.038)	0.000340
		HGB	0.134 (0.038)	0.000437
		Magnesium	0.133 (0.038)	0.000458
H6	Dodecenoylcarnitine	Serum creatinine	-0.097 (0.031)	0.001950
		eGFRcrea	-0.106 (0.032)	0.000792
		PLT	-0.117 (0.032)	0.000264
	Hydroxyvalerylcarnitine (Methylmalonylcarnitine)	Serum creatinine	-0.108 (0.032)	0.000645
		eGFRcrea	-0.114 (0.032)	0.000322
		PLT	-0.122 (0.032)	0.000129
	Tiglylcarnitine	Serum creatinine	-0.097 (0.032)	0.002170
		eGFRcrea	-0.103 (0.032)	0.001130
		PLT	-0.115 (0.032)	0.000336
H10	Glutamine	Magnesium	-0.197 (0.051)	0.000104
	Putrescine	Magnesium	-0.195 (0.053)	0.000239

Figure legends

Figure 1. Analysis setting. **Panel A.** Analysis flowchart. **Panel B.** Regional association plot depicting associations between variants in and around the *FAM47E-SHROOM3* locus in the CHRIS study, reflecting a similar association pattern as that identified by a recent CKDGen GWAS meta-analysis⁴: the most associated SNP in the CKDGen analysis is highlighted in purple. SNP positions are referred to the NCBI Build 38. Plot generated with LocusZoom v1.4⁵⁷.

Figure 2. Characteristics of the variants included in the *FAM47E-SHROOM3* region on chromosome 4 (76,251,700-76,516,500 bp). **Panel A.** Minus \log_{10} P-values of the significant associations between any of the 146 variants used for haplotype reconstruction and 18 GWAS Catalog traits that are also present in the CHRIS study. Colors and shapes of the dots are used to distinguish the different genes the variants belong to. Traits: creatinine-based estimated glomerular filtration rate, eGFR_{crea}; serum creatinine, SCr; hematocrit, HCT; red blood cell count, RBC; hemoglobin, HGB; alanine transaminase, ALT GPT; height; serum albumin, SA_{lb}; alkaline phosphatase, ALP; aspartate aminotransferase, AST GOT; triglycerides, TG; urine albumin-creatinine ratio, UACR; serum magnesium; low-density lipoprotein (LDL) cholesterol; platelet count, PLT; mean corpuscular hemoglobin, MCH; systolic blood pressure, SBP; and body mass index, BMI. **Panel B.** Barplot of the most severe consequences of the 146 variants identified for haplotype reconstruction. **Panel C.** Linkage disequilibrium pattern of the *FAM47E-SHROOM3* locus, based on the D' statistic. Included are variants associated with complex traits from previous genome-wide association studies and haplotype-tagging variants. The labels on x- and y-axis are annotated by the corresponding gene symbol and RSID. On the vertical axis, we also report the associated complex trait, as per GWAS Catalog interrogation. Variants' RSID color coding indicates: the most associated variant, rs28817415, with eGFR_{crea}⁵ (orange); 25 of the 27 haplotype-tagging variants (two variants were not represented in the LD reference panel) (purple); and 31 variants for which there was a GWAS Catalog genome-wide significant association with a trait among those included in the CHRIS study (black). **Panel D.** Distribution of the 11 reconstructed haplotypes, identified by 27 tagging variants with their functional consequences given on the x-axis. Haplotype frequencies are reported right of the haplotype label for the three analyzed subsamples in the order: all individuals with clinical traits; those with also metabolites measurements; those with additional protein measurements.

Figure 3. Association of the 27 haplotype-tagging variants with gene expression and protein levels. **Panel A:** Normalized effect size of association between the 27 haplotype-tagging variants and expression of *FAM47E*, *STBD1*, and *CCDC158* (horizontal axis; genes grouped by variant) across 46 tissues (vertical axis) retrieved from the GTEx v8 dataset. Uterus and vagina tissues and *SHROOM3* were omitted for the lack of significant results. **Panel B:** Normalized effect size for association between the 27 haplotype-tagging variants (horizontal axis) and protein concentrations (vertical axis) retrieved from the deCODE dataset ³⁴. Listed are only proteins with a significant association with at least one variant.

Figure 4. Hierarchical cluster analysis of z-scores from the associations between haplotypes with any of the 13 clinical traits and 7 metabolites that were associated with at least one haplotype (indicated with *), in the subset of study participants with metabolites measurements available. Haplotype H5 was excluded as it did not reach the 2% frequency in this subsample.

References

1. Köttgen A, Glazer NL, Dehghan A, et al. Multiple loci associated with indices of renal function and chronic kidney disease. *Nat Genet.* Jun 2009;41(6):712-717. doi:10.1038/ng.377
2. Köttgen A, Pattaro C, Böger CA, et al. New loci associated with kidney function and chronic kidney disease. *Nat Genet.* May 2010;42(5):376-384. doi:10.1038/ng.568
3. Pattaro C, Köttgen A, Teumer A, et al. Genome-Wide Association and Functional Follow-Up Reveals New Loci for Kidney Function. *PLoS Genetics.* 2012;8(3):e1002584. doi:10.1371/journal.pgen.1002584
4. Wuttke M, Li Y, Li M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. *Nat Genet.* Jun 2019;51(6):957-972. doi:10.1038/s41588-019-0407-x
5. Stanzick KJ, Li Y, Schlosser P, et al. Discovery and prioritization of variants and genes for kidney function in >1.2 million individuals. *Nature Communications.* 2021/07/16 2021;12(1):4350. doi:10.1038/s41467-021-24491-0
6. Pattaro C, De Grandi A, Vitart V, et al. A meta-analysis of genome-wide data from five European isolates reveals an association of COL22A1, SYT1, and GABRR2 with serum creatinine level. *BMC Med Genet.* Mar 11 2010;11:41. doi:10.1186/1471-2350-11-41
7. Teumer A, Chaker L, Groeneweg S, et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. *Nature Communications.* 2018/10/26 2018;9(1):4455. doi:10.1038/s41467-018-06356-1
8. Hildebrand JD, Soriano P. Shroom, a PDZ domain-containing actin-binding protein, is required for neural tube morphogenesis in mice. *Cell.* Nov 24 1999;99(5):485-497. doi:10.1016/s0092-8674(00)81537-8
9. Yeo NC, O'Meara CC, Bonomo JA, et al. Shroom3 contributes to the maintenance of the glomerular filtration barrier integrity. *Genome Res.* Jan 2015;25(1):57-65. doi:10.1101/gr.182881.114
10. Prokop JW, Yeo NC, Ottmann C, et al. Characterization of Coding/Noncoding Variants for SHROOM3 in Patients with CKD. *J Am Soc Nephrol.* May 2018;29(5):1525-1535. doi:10.1681/asn.2017080856
11. Khalili H, Sull A, Sarin S, et al. Developmental Origins for Kidney Disease Due to Shroom3 Deficiency. *J Am Soc Nephrol.* Oct 2016;27(10):2965-2973. doi:10.1681/asn.2015060621
12. Matsuura R, Hiraishi A, Holzman LB, et al. SHROOM3, the gene associated with chronic kidney disease, affects the podocyte structure. *Scientific Reports.* 2020/12/03 2020;10(1):21103. doi:10.1038/s41598-020-77952-9
13. Lemay P, Guyot MC, Tremblay É, et al. Loss-of-function de novo mutations play an important role in severe human neural tube defects. *J Med Genet.* Jul 2015;52(7):493-497. doi:10.1136/jmedgenet-2015-103027
14. Deshwar AR, Martin N, Shannon P, Chitayat D. A homozygous pathogenic variant in SHROOM3 associated with anencephaly and cleft lip and palate. *Clin Genet.* Sep 2020;98(3):299-302. doi:10.1111/cge.13804
15. Durbin MD, O'Kane J, Lorentz S, Firulli AB, Ware SM. SHROOM3 is downstream of the planar cell polarity pathway and loss-of-function results in congenital heart defects. *Dev Biol.* Aug 15 2020;464(2):124-136. doi:10.1016/j.ydbio.2020.05.013
16. Chen MH, Raffield LM, Mousas A, et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. *Cell.* Sep 3 2020;182(5):1198-1213.e1114. doi:10.1016/j.cell.2020.06.045
17. Meyer TE, Verwoert GC, Hwang SJ, et al. Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. *PLoS Genet.* Aug 5 2010;6(8)doi:10.1371/journal.pgen.1001045

18. Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat Genet.* Oct 2017;49(10):1511-1516. doi:10.1038/ng.3955
19. Wei C, Banu K, Garzon F, et al. SHROOM3-FYN Interaction Regulates Nephron Phosphorylation and Affects Albuminuria in Allografts. *J Am Soc Nephrol.* Nov 2018;29(11):2641-2657. doi:10.1681/asn.2018060573
20. Ghasemi-Semeskandeh D, Emmert D, König E, et al. Systematic mediation and interaction analyses in an individual population study help characterize kidney function genetic loci. *medRxiv.* 2023:2023.2004.2015.23288540. doi:10.1101/2023.04.15.23288540
21. Pattaro C, Gögele M, Mascialzoni D, et al. The Cooperative Health Research in South Tyrol (CHRIS) study: rationale, objectives, and preliminary results. *Journal of Translational Medicine.* 2015/11/05 2015;13(1):348. doi:10.1186/s12967-015-0704-9
22. Arisido MW, Foco L, Shoemaker R, et al. Cluster analysis of angiotensin biomarkers to identify antihypertensive drug treatment in population studies. *BMC Med Res Methodol.* May 27 2023;23(1):131. doi:10.1186/s12874-023-01930-8
23. König E, Rainer J, Hernandez VV, et al. Whole Exome Sequencing Enhanced Imputation Identifies 85 Metabolite Associations in the Alpine CHRIS Cohort. *Metabolites.* 2022;12(7):604.
24. Emmert DB, Vukovic V, Dordevic N, et al. Genetic and Metabolic Determinants of Atrial Fibrillation in a General Population Sample: The CHRIS Study. *Biomolecules.* 2021;11(11):1663.
25. Pattaro C, Riegler P, Stifter G, Modenese M, Minelli C, Pramstaller PP. Estimating the glomerular filtration rate in the general population using different equations: effects on classification and association. *Nephron Clin Pract.* 2013;123(1-2):102-111. doi:10.1159/000351043
26. Noce D, Gögele M, Schwenbacher C, et al. Sequential recruitment of study participants may inflate genetic heritability estimates. *Hum Genet.* Jun 2017;136(6):743-757. doi:10.1007/s00439-017-1785-8
27. Verri Hernandez V, Dordevic N, Hantikainen EM, et al. Age, Sex, Body Mass Index, Diet and Menopause Related Metabolites in a Large Homogeneous Alpine Cohort. *Metabolites.* 2022;12(3):205.
28. Messner CB, Demichev V, Bloomfield N, et al. Ultra-fast proteomics with Scanning SWATH. *Nat Biotechnol.* Jul 2021;39(7):846-854. doi:10.1038/s41587-021-00860-4
29. Dordevic N, Dierks C, Hantikainen E, et al. Pervasive Influence of Hormonal Contraceptives on the Human Plasma Proteome in a Broad Population Study. *medRxiv.* 2023:2023.2010.2011.23296871. doi:10.1101/2023.10.11.23296871
30. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score Tests for Association between Traits and Haplotypes when Linkage Phase Is Ambiguous. *The American Journal of Human Genetics.* 2002/02/01/ 2002;70(2):425-434. doi:<https://doi.org/10.1086/338688>
31. Lewontin RC. On measures of gametic disequilibrium. *Genetics.* Nov 1988;120(3):849-852. doi:10.1093/genetics/120.3.849
32. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience.* 2015;4(1)doi:10.1186/s13742-015-0047-8
33. Han SK, McNulty MT, Benway CJ, et al. Mapping genomic regulation of kidney disease and traits through high-resolution and interpretable eQTLs. *Nat Commun.* Apr 19 2023;14(1):2229. doi:10.1038/s41467-023-37691-7
34. Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma proteome with genetics and disease. *Nat Genet.* Dec 2021;53(12):1712-1721. doi:10.1038/s41588-021-00978-w
35. Wang TJ, Evans JC, Meigs JB, et al. Low-Grade Albuminuria and the Risks of Hypertension and Blood Pressure Progression. *Circulation.* 2005;111(11):1370-1376. doi:doi:10.1161/01.CIR.0000158434.69180.2D

36. Indiveri C, Iacobazzi V, Tonazzi A, et al. The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology. *Molecular Aspects of Medicine*. 2011/08/01/ 2011;32(4):223-233. doi:<https://doi.org/10.1016/j.mam.2011.10.008>
37. Goek O-N, Döring A, Gieger C, et al. Serum Metabolite Concentrations and Decreased GFR in the General Population. *American Journal of Kidney Diseases*. 2012/08/01/ 2012;60(2):197-206. doi:<https://doi.org/10.1053/j.ajkd.2012.01.014>
38. Fouque D, Holt S, Guebre-Egziabher F, et al. Relationship Between Serum Carnitine, Acylcarnitines, and Renal Function in Patients With Chronic Renal Disease. *Journal of Renal Nutrition*. 2006/04/01/ 2006;16(2):125-131. doi:<https://doi.org/10.1053/j.jrn.2006.01.004>
39. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. *Kidney international*. 2006;70(2):246-250.
40. Watanabe M, Suliman ME, Qureshi AR, et al. Consequences of low plasma histidine in chronic kidney disease patients: associations with inflammation, oxidative stress, and mortality. *Am J Clin Nutr*. 2008/06// 2008;87(6):1860-1866. doi:10.1093/ajcn/87.6.1860
41. Vera-Aviles M, Vantana E, Kardinajari E, Koh NL, Latunde-Dada GO. Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. *Pharmaceuticals*. 2018;11(4):111.
42. Sieckmann T, Schley G, Ögel N, et al. Strikingly conserved gene expression changes of polyamine regulating enzymes among various forms of acute and chronic kidney injury. *Kidney Int*. Jul 2023;104(1):90-107. doi:10.1016/j.kint.2023.04.005
43. Saito A, Takagi T, Chung TG, Ohta K. Serum levels of polyamines in patients with chronic renal failure. *Kidney Int Suppl*. Dec 1983;16:S234-237.
44. Luo Q, Liang W, Zhang Z, et al. Compromised glycolysis contributes to foot process fusion of podocytes in diabetic kidney disease: Role of ornithine catabolism. *Metabolism*. Sep 2022;134:155245. doi:10.1016/j.metabol.2022.155245
45. Yasuda-Yamahara M, Kume S, Maegawa H. Roles of mTOR in Diabetic Kidney Disease. *Antioxidants (Basel)*. Feb 22 2021;10(2)doi:10.3390/antiox10020321
46. Stumvoll M, Perriello G, Meyer C, Gerich J. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. *Kidney International*. 1999/03/01/ 1999;55(3):778-792. doi:<https://doi.org/10.1046/j.1523-1755.1999.055003778.x>
47. Miller RA, Shi Y, Lu W, et al. Targeting hepatic glutaminase activity to ameliorate hyperglycemia. *Nat Med*. May 2018;24(4):518-524. doi:10.1038/nm.4514
48. Sadar S, Kaspate D, Vyawahare N. Protective effect of L-glutamine against diabetes-induced nephropathy in experimental animal: Role of KIM-1, NGAL, TGF- β 1, and collagen-1. *Ren Fail*. Oct 2016;38(9):1483-1495. doi:10.1080/0886022x.2016.1227918
49. Samocha-Bonet D, Chisholm DJ, Gribble FM, et al. Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study. *PLoS One*. 2014;9(11):e113366. doi:10.1371/journal.pone.0113366
50. Del Bosque-Plata L, Hernández-Cortés EP, Gragnoli C. The broad pathogenetic role of TCF7L2 in human diseases beyond type 2 diabetes. *J Cell Physiol*. Jan 2022;237(1):301-312. doi:10.1002/jcp.30581
51. Chung JJ, Goldstein L, Chen YJ, et al. Single-Cell Transcriptome Profiling of the Kidney Glomerulus Identifies Key Cell Types and Reactions to Injury. *J Am Soc Nephrol*. Oct 2020;31(10):2341-2354. doi:10.1681/asn.2020020220
52. Antonelli A, Ferrari SM, Mancusi C, et al. Interferon- α , - β and - γ induce CXCL11 secretion in human thyrocytes: Modulation by peroxisome proliferator-activated receptor γ agonists. *Immunobiology*. 2013/05/01/ 2013;218(5):690-695. doi:<https://doi.org/10.1016/j.imbio.2012.08.267>
53. Leberherz-Eichinger D, Klaus DA, Reiter T, et al. Increased chemokine excretion in patients suffering from chronic kidney disease. *Translational Research*. 2014/12/01/ 2014;164(6):433-443.e432. doi:<https://doi.org/10.1016/j.trsl.2014.07.004>

54. Sampson MG, Robertson CC, Martini S, et al. Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects. *Journal of the American Society of Nephrology*. 2016;27(3)
55. Panzer U, Steinmetz OM, Paust H-J, et al. Chemokine Receptor CXCR3 Mediates T Cell Recruitment and Tissue Injury in Nephrotoxic Nephritis in Mice. *Journal of the American Society of Nephrology*. 2007;18(7):2071-2084. doi:10.1681/asn.2006111237
56. Palese F, Pontis S, Realini N, et al. Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism. *Pharmacol Res*. Aug 2022;182:106338. doi:10.1016/j.phrs.2022.106338
57. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*. 2010;26(18):2336-2337. doi:10.1093/bioinformatics/btq419

Figure 1.








Figure 2.



D

SNP	Ref.	0.244	0.237	0.239
FAM47E rs17001726	A	C	C	C
FAM47E rs61740422	G	G	T	G
FAM47E rs2289514	T	T	G	G
FAM47E rs1876538				
FAM47E rs3733253				
FAM47E rs3733251				
FAM47E rs3733250				
FAM47E rs6532316				
FAM47E rs6812193				
FAM47E rs3817118				
FAM47E rs964051				
FAM47E rs1036788				
FAM47E rs1542096				
FAM47E-STBD1 rs3733249				
FAM47E-STBD1 rs3733248				
CCDC158 rs112525409				
CCDC158 rs7658585				
CCDC158 rs113022439				
CCDC158 rs114878412				
CCDC158 rs12504985				
CCDC158 rs72657825				
CCDC158 rs116383392				
CCDC158 rs6844174				
CCDC158 rs17001890				
CCDC158 rs80162610				
CCDC158 rs6857452				
SHROOM3 rs10006043				

Ref., 0.244, 0.237, 0.239

H10, 0.030, 0.034, 0.029

H9, 0.040, 0.038, 0.038

H8, 0.027, 0.030, 0.034

H7, 0.024, 0.025, 0.028

H6, 0.116, 0.118, 0.122

H5, 0.020, <0.02, <0.02

H4, 0.028, 0.028, 0.024


H3, 0.023, 0.025, 0.026

H2, 0.035, 0.035, 0.035

H1, 0.076, 0.071, 0.062

Figure 3.

A



B





Figure 4.




Supplementary materials


Supplementary Methods

Haplotypes were reconstructed using the expectation-maximization algorithm implemented in the R package 'haplo.stats' v1.8.9 with the following parameter setting: n.try=2 (number of times to try to maximize the log-likelihood); insert.batch.size=2 (number of loci to be inserted in a single batch); max.haps.limit=4e6 (maximum number of haplotypes for the input genotypes); and min.posterior=1e-5 (minimum posterior probability for a haplotype pair, given the input genotypes).

Supplementary Figure 1. Interrogation of the 146 variants in association with any complex trait in the GWAS Catalog. Minus \log_{10} P-values of the significant associations are presented. Only genome-wide significant associations ($P\text{-value} < 5 \times 10^{-8}$) are presented. Colors and shapes of the dots are used to distinguish the different genes to which the variants belong.



Supplemental Figure 3. Haplotype association analysis results. Displayed are the effect coefficients and their 95% confidence intervals from the associations between haplotypes with the 13 clinical traits and 7 metabolites that were associated with at least one haplotype, in the subset of participants with metabolites measurements available. Haplotype 5 (H5) was excluded as it did not reach the 2% frequency in this subsample.



Supplemental Figure 4. Cluster analysis of the standardized effects of haplotypes on significant clinical traits and metabolites. **Panel A.** Results of the Silhouette method applied to the clustering of haplotypes: the number of clusters (x-axis) is plotted against the average silhouette width (y-axis). **Panel B.** Results of the Silhouette method applied to the clustering of traits: the number of clusters (x-axis) is plotted against the average silhouette width (y-axis). **Panel C.** Hierarchical clustering of haplotypes (listed and clustered on the y-axis). **Panel D.** Hierarchical clustering of clinical traits and metabolites (listed and clustered on the y-axis). Colors are used to identify the clusters.

